Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Cash from Investing Activities (2012 - 2026)

Kamada's (KMDA) quarterly Cash from Investing Activities came in at -$2.5 million in Q2 2026, down 26.22% on a YoY basis from -$3.4 million in Q2 2025, and up 93.83% quarter-over-quarter from -$41.2 million in Q1 2026.

Analysis

Kamada (KMDA) Cash from Investing Activities (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Cash from Investing Activities for 15 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash from Investing Activities fell 26.22% year-over-year to -$2.5 million; the trailing twelve-month figure through Jun 2026 stood at -$50.1 million (down 487.94% YoY), and the FY2025 full-year result was -$9.8 million, up 8.39% from the prior year.
  • Cash from Investing Activities climbed to -$2.5 million in Q2 2026 per KMDA's latest filing, from -$41.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$513000.0 in Q1 2022 and bottomed at -$41.2 million in Q1 2026.
  • Historically, Cash from Investing Activities has averaged -$4.1 million across 5 years, with a median of -$2.0 million in 2023.
  • The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities soared 98.98% in 2022, then sank 2721.78% in 2026.
  • Over 5 years, Cash from Investing Activities stood at -$977000.0 in 2022, then slumped by 101.94% to -$2.0 million in 2023, then plunged by 48.2% to -$2.9 million in 2024, then rose by 5.1% to -$2.8 million in 2025, then increased by 8.4% to -$2.5 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered -$2.5 million, -$41.2 million, and -$2.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -569.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn -10.35 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -45.80 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn -92.70 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 329.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn -363.46 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -3.84 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 281.26 Mn
10 Kamada 473.57 Mn 403.43 Mn 22.47 Mn -2.54 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.54 Mn
Mar 31, 2026 -41.20 Mn
Dec 31, 2025 -2.78 Mn
Sep 30, 2025 -3.59 Mn
Jun 30, 2025 -2.01 Mn
Mar 31, 2025 -1.46 Mn
Dec 31, 2024 -2.92 Mn
Sep 30, 2024 -2.12 Mn
Jun 30, 2024 -3.01 Mn
Mar 31, 2024 -2.68 Mn
Dec 31, 2023 -1.97 Mn
Sep 30, 2023 -1.73 Mn
Jun 30, 2023 -1.05 Mn
Mar 31, 2023 -1.09 Mn
Dec 31, 2022 -977,000.00
Sep 30, 2022 -1.62 Mn
Jun 30, 2022 -678,000.00
Mar 31, 2022 -513,000.00
Dec 31, 2021 -95.74 Mn
Sep 30, 2021 34.59 Mn